A Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2018
At a glance
- Drugs INO 1400 (Primary) ; INO 9012 (Primary)
- Indications Breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; Head and neck cancer; Liver cancer; Lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Inovio Pharmaceuticals
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Nov 2017 Planned number of patients changed from 54 to 90.
- 15 Nov 2016 New trial record